Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30575805 | 1.00 | TRPV1 (0.50) | TRPV1TRPA1TSHRTDP1ALDH1A1 | |
| SCHEMBL8582465 | 1.00 | TRPV1 (0.50) | TRPV1TRPA1TSHRTDP1ALDH1A1 | |
| SCHEMBL5136481 | 1.00 | TRPV1 (0.50) | TRPV1TRPA1TSHRTDP1ALDH1A1 | |
| SCHEMBL5014042 | 1.00 | TRPV1 (0.50) | TRPV1TRPA1TSHRTDP1ALDH1A1 | |
| SCHEMBL11384575 | 1.00 | TRPV1 (0.50) | TRPV1TRPA1TSHRTDP1ALDH1A1 | |
| SCHEMBL4443550 | 1.00 | TRPV1 (0.50) | TRPV1TRPA1TSHRTDP1ALDH1A1 | |
| SCHEMBL17002461 | 1.00 | TRPV1 (0.50) | TRPV1TRPA1TSHRTDP1ALDH1A1 | |
| SCHEMBL6285447 | 1.00 | TRPV1 (0.50) | TRPV1TRPA1TSHRTDP1ALDH1A1 | |
| SCHEMBL5136479 | 1.00 | TRPV1 (0.50) | TRPV1TRPA1TSHRTDP1ALDH1A1 | |
| SCHEMBL30787232 | 1.00 | TRPV1 (0.50) | TRPV1TRPA1TSHRTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4463534-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID MULTIMERS | The Procter & Gamble Company (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023137409-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID MULTIMERS | THE PROCTER & GAMBLE COMPANY (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20230220300-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID MULTIMERS | THE PROCTER & GAMBLE COMPANY | 2023-07-13 | — | — | US | disclosed |
| EP-1082008-A1 | PHEROMONES | Löfqvist, Jan (SE) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999059408-A1 | PHEROMONES | LOEFQVIST JAN (SE) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220300-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID MULTIMERS | BCAT2, MTR, ASNS | TRPV1 2564/4885TRPA1 1162/4885TSHR 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.